Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 8/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 8/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4797785 | 0.88 | HDAC6 (0.47) | HDAC6HDAC1HDAC4HSP90AA1HSP90AB1 | |
| SCHEMBL4799051 | 0.87 | HSP90AB1 (0.46) | HDAC6HDAC1HDAC4HSP90AA1HSP90AB1 | |
| SCHEMBL3269020 | 0.80 | ADORA2A (0.43) | HDAC6HDAC1HDAC4HSP90AA1HSP90AB1 | |
| SCHEMBL3268049 | 0.80 | ADORA2A (0.65) | HDAC6HDAC1HDAC4ADORA2AADORA1 | |
| SCHEMBL12072478 | 0.79 | HSP90AB1 (0.46) | HDAC6HDAC1HDAC4HSP90AA1HSP90AB1 | |
| SCHEMBL3273456 | 0.79 | ADORA2A (0.50) | HDAC6HDAC1HDAC4HSP90AA1HSP90AB1 | |
| SCHEMBL3269601 | 0.79 | HDAC6 (0.44) | HDAC6HDAC1HDAC4HSP90AA1HSP90AB1 | |
| SCHEMBL9663203 | 0.79 | HDAC6 (0.47) | HDAC6HDAC1HDAC4HSP90AA1HSP90AB1 | |
| SCHEMBL2153079 | 0.78 | HDAC6 (0.56) | HDAC6HDAC1HDAC4HSP90AA1HSP90AB1 | |
| SCHEMBL17040218 | 0.77 | HSP90AB1 (0.47) | HDAC6HDAC1HDAC4HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108997429-B | Method for preparing Beciclovir | 广州粤美医药科技有限公司 | 2020-10-30 | — | — | CN | disclosed |
| EP-1349857-B1 | PURINE DERIVATIVES AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RES LTD (GB) | 2010-06-16 | — | — | EP | disclosed |
| US-7452894-B2 | Purine derivatives as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2008-11-18 | — | — | US | disclosed |
| US-20060270691-A1 | Purine derivatives as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED | 2006-11-30 | — | — | US | disclosed |
| US-20040102459-A1 | Purine derivatives as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2004-05-27 | — | — | US | disclosed |
| EP-1349857-A1 | PURINE DERIVATIVES AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2003-10-08 | — | — | EP | disclosed |
| WO-2002055521-A1 | PURINE DERIVATIVES AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2002-07-18 | — | — | WO | disclosed |
| WO-1993007881-A1 | INHIBITION OF VIRUSES BY THE ADMINISTRATION OF HOMOPOLYRIBONUCLEOTIDES AND/OR DUPLEX POLYMERS | UNIVERSITY OF UTAH (US) | 1993-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270691-A1 | Purine derivatives as purinergic receptor antagonists | CHRNA10, CHRNA5, CHRNA4 | HDAC6 3406/4885HDAC1 3044/4885HDAC4 2737/4885 |
| US-20040102459-A1 | Purine derivatives as purinergic receptor antagonists | OPRL1, CNR1, CNR2 | HDAC6 2987/4885HDAC1 2681/4885HDAC4 2490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.